Although we examined clinical samples of only five brain tumor patients, in all five cases, the TAT, which in our cases corresponds to NAT, had a different mycobiome composition from the tumor mycobiome, similar to that observed in breast cancer. This evidence concerns the gene BRD2 and brain neoplasm.